Communiqués Petros Pharmaceuticals

Actions

PTPI

US71678J3086

Marché Fermé - OTC Markets 21:21:43 09/09/2026			Varia. 5j.	Varia. 1 janv.
0,008000 ^USD	+28,00 %		+70,21 %	+0,63 %

13/08	Petros Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
18/06	Petros Pharmaceuticals, Inc. annonce des changements au sein de sa direction, effectifs au 18 juin 2026	CI

Communiqués

22/05/25	Petros Pharmaceuticals Announces Transition from NASDAQ to OTC Markets	AQ
06/05/25	Petros Pharmaceuticals Strengthens Partnership with Market Leading Big Data Provider Implementing Key Enhancements to its AI Platform	AQ
01/05/25	Petros Pharmaceuticals Developing First-in-Industry SaaS Platform Utilizing AI and Electronic Health Records Intended to Facilitate Rx-OTC Switches	AQ
29/04/25	Petros Proprietary Technology Platform Aligns with April 15, 2025 President Trump Executive Order Advancing Rx-to-OTC Reclassification Reforms	AQ
28/03/25	Sekur Private Data Ltd. (OTCQB: SWISF) (CSE: SKUR): Cybersecurity Platform Redefines Privacy	AQ
27/03/25	"Cybersecurity, Healthcare Innovators PTPI, SWISF, OCEA, DGLY, LYT, SIGL, Amid FBI Warnings, Signal App Breach, and Data Privacy Crisis"	AQ
20/03/25	Petros Pharmaceuticals : to Partner with Renowned Big Data Provider to Enable Rx to OTC Switch Across Multiple Indications	PU
20/03/25	Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications	AQ
19/02/25	Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants	AQ
18/12/24	Petros Pharmaceuticals - Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market valued at over $38 Billion annually	AQ
16/12/24	Petros Pharmaceuticals : Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement Form 8 K	PU
14/11/24	Petros Pharmaceuticals : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
12/09/24	Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA	AQ
17/07/24	Petros Pharmaceuticals STENDRA Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance	AQ
30/05/24	Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA OTC Switch	AQ
25/04/24	Petros Pharmaceuticals announces online distribution for lead ED product with Lemonaid Health	AQ
24/04/24	Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA through New Agreement with Lemonaid Health	AQ
11/03/24	BestGrowthStocks.Com Issues Comprehensive Analysis of Petros Pharmaceuticals Inc	AQ
25/01/24	Petros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA Rx-to-OTC Switch	AQ
18/01/24	Petros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA Rx-to-OTC Switch	AQ
13/12/23	Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology Provider	AQ
13/12/23	Petros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA the First Erectile Dysfunction Medication to Achieve OTC Status	AQ
31/10/23	Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA	AQ
29/09/23	Petros Pharmaceuticals to Present at the LD Micro Main Event XVI	AQ
15/09/23	Petros Pharmaceuticals : Modification to Rights of Security Holders - Form 8-K	PU